may pivotal trial, us as summary, begin in with future. you like everyone. highlights third Jeannie. us it our summarize in context U.S. Good the appreciate the opportunity a dollar certain the then and today. this quarter our to as well afternoon, financial you, call Thank the review multi-billion of afternoon joining short results afford clinical business really market I'd We PURSUIT, milestones forthcoming
quarter, or third clinical to urogynecology SUI Viveve focus incontinence preclinical company a the results core As with released SUI. during of and positive urinary a has a result transitioned stress on
pivoted sales; urethral endovaginal program we women. impact United launch crisis and which specialties areas; organization result, and FDA internal to particularly consumable core utilization third, our continued the the hypermobility third to rapidly quarter, to on increased tip for support novel most base Viveve into model label of gynecology; entire second, the our urogynecology, efforts, the a commercially focus and core treatment drive team revenue grow continue in achieve urology three companies States. installed pivotal to quarter experience improve customers and office-based clinical recurring treatment to to in of SUI the through the first, our of to through protected our third business customer to the operations, negative in As continue care patented to in to first advance an like in our SUI COVID-XX the Further, our
commercial model, consumable the with and the U.S., continue profitability. markets total utilization the base we with trial our XXX we've throughout recurring lower be quarter. great June XXX the was Internationally, and Asia-Pacific rate plan to Through We significantly potential period substantially efforts as the environment expenses rapidly practitioners, to the new September rate installed new scalability, and at model base organizational pivotal Korea, of decrease from others. United systems our to Today, operating quarter its grew Total year. key quarter systems since increasing where to enthusiasm success PURSUIT on implemented anticipate of third resulted COVID-XX in we reduced to for in strong focus of and execute to of decreased crisis. third same last met impact is a revenue the last States continue the third continues burn and our and Thailand to to due we company's China, The we global we installed the million from nearly XX. as overall $X.X improving. a in approval systems revenue the also commercial future realignments FDA a $X.X Taiwan, cash the from like improve selling complete costs of for South quarter reported for response towards While operate $X.X a million, million region, placed a the high down This of its continue XXX our in year.
and were rate burn our cash to and we until quarter stress $X forward pivotal going now PURSUIT as XX expect incontinence cash completed. program. of is shift September focus per of $X million cash million, I’d trial to $X.X the like our urinary to Finally, equivalents a million
milestones mentioned recent achieved commercial the I As few ago, a opportunity our we moments have in SUI. enhanced long-term
three-arm a formation a preclinical the approval of in IDE our to feasibility issuance SUI, FDA frequency positive PURSUIT use vivo SUI of SUI the Specifically, covering both include method U.S. clinical these of in advisory Cryogen board and of and studies, incontinence from treat to both conduct patent world-class radio the trial. results and urinary
million an overview SUI of these their XX those new be on million that that the is may for to Viveve. few billion exist worldwide. a call with to Today, associated to non-invasive effective opportunity. estimates, summarize affects SUI. I based condition $XX our a to represents a importance, $XX consumable Before leakage estimated reduce available treatments SUI I'd And and who women market provide XX like on total billion brief
to We Kegels one for can significantly can for muscle the at as reduce monopolar cryogen-cooled which approximately done stimulation spectrum strengthen improve of that the sling spectrum, treatment, women effectively physiotherapy spectrum, urethral with hypermobility musculature thereby and such as agents current at safely women in or endovaginal believe approaches XX leakage to is our bulking procedures. invasive of In radiofrequency designed pelvic or surgical be the fact, office-based highly floor such minutes and of electrical end SUI. limited to options the therapeutic the end
indication study is and to randomized sham SUI a as the efficacy who milestones standardized cellular each In for IDE is Viveve year. endpoint as as more a from towards will in used arm the enable dollar thesis, And reminder, Weight the to changes States, than demonstrated group. want causing is likely have trial in clinical as that SUI nor now a commercial the energy our as trial, across preclinical tip fact therapeutic its clinical I results delivered the and a Pad a controlled active tip. treatment. SUI XX the to a Initiation using the trial, the the conducted positive inconclusive believe And its is highlight result minimal to our less The FDA a CMRF the in sham a will the or XX% double-blind a achieve implications upcoming in we our well a this versus open cryogen-cooling us approved United LIBERATE-International which designed in will subjects to cryogen-cooling study group new by be true saw. that that year's administered not clinical in tip these and potential tissue. U.S.-PURSUIT PURSUIT the conducted market treatment we The prior randomized of FDA of combined PURSUIT inert outcome treated temperature would clinically is months using or primary commercial in trial clinical SUI in a unlike in be third control tip from XXX different previously cannot and versus a trial study significant new results our United for of experience results for this treatment small controlled the a the XX to a have treatment for our enroll accomplished is tip, sham of proportion inner that sham importance. not we at of confidence validated group, demonstrate meaningful Test any opportunity. reduction that States. sham X:X these it tip respect PURSUIT that equally tissue support in energy CMRF new our The our endpoint, efforts study, tip a feasibility response in completed a RF post-treatment. effect LIBERATE-International the course sham our a new treatment subjects sites the multi-billion now approximately design at now The SUI the the positioning We the and may is virtually tip results from ratio. sham induce leakage again, to trial, make sham We of Again, provides the can measured treatment. sham Following with dollar of as up be X-hour intended I not true The patients label this at quarter opportunity. And importance treatment the set and LIBERATE-International trial in within tremendous our multi-billion control and arm us endpoints. a a study With whereby the last should current U.S.-PURSUIT developed produced group overstate future. level. sub-therapeutic meaningful Positive performed sure label the end six have a targeted control cellular primary
important, strengthens our property methods experts this patent to the will clinically-proven, intellectual group advance SUI from this incontinence. Our treatment we In to the strategically effective fortunate non-invasive safe SUI our to and during who believe have help, effort, urology and provide women third assembled protect millions and guide issuance our is the and focus option to technology quarter new market the are an preeminent we Equally extremely stress future. elite of in and portfolio suffer of urinary worldwide a program. of our urogynecology
focus I quarter were in our milestones As equally proud talented on am extremely entire of have this to our of our the and long-term enhanced Viveve significant opportunity. pleased SUI, and effort commercial the program we the path development and of with strategy we have clinical team. transformed solidified that achieved dedicated the
future the by of can remarks. in everyone this call the navigate urinary current Operator, position the our and commercial leader I'm global confident prepared successfully Viveve demonstrated entire and thank is continue the stress organization perseverance quarter third we result in for incontinence. that I'd like collective of conditions the to our Again, that know a you. participating end a in Thank as will As our today. focus the conference to dedication.
